BIVDA Press Releases

Jun 23, 2021
BIVDA Comments on new Government Clinical Research Implementation Plan BIVDA has commented on the new Government plan to boost clinical research – ‘The Future of UK Clinical Research Delivery.’ The strategy builds on existing commitments and is intended to bring research and greater investment to our shores, bolstering our economic growth, tackling health inequalities and improving the health of people right across the UK. The strategy contains five key themes:  ...
Read More
Jun 14, 2021
BIVDA has launched the latest in its series of strategic papers, ‘The Digital Revolution’.  BIVDA is publishing this paper to ensure that the digitisation of In vitro Diagnostics (IVD) and the breakthroughs, experiences and collaboration resultant from the coronavirus pandemic are not limited to being a short-term phenomenon. The last year has demonstrated that the IVD industry has the ability and capacity to transform healthcare through an early diagnosis culture which prevents...
Read More
Jun 08, 2021
BIVDA responds to G7 Communique on antimicrobial resistance (AMR) BIVDA has responded to the communique published by the attendees at the G7 meeting in Cornwall, pledging to do more to tackle the problem of AMR. Across the world, AMR is responsible for hundreds of thousands of avoidable deaths a year and the numbers are increasing year on year by 4% - and will continue to do so as current antibiotics lose their effectiveness against new and evolving strains of bacteria.  Commentin...
Read More
Jun 02, 2021
BIVDA offers industry support to Government for COP26 climate goals BIVDA, the trade association for in-vitro diagnostic companies, has written to the President of COP26, Alok Sharma MP, to offer the support of the industry for the forthcoming COP26 summit in Glasgow. BIVDA and its members have been at the forefront of our response to the pandemic, working closely with colleagues at NHS England the Department for Health and Social Care during this challenging period. As part of this cr...
Read More
May 26, 2021
Press Release                                                                                 &...
Read More
May 21, 2021
The British In-Vitro Diagnostic Association (BIVDA) has launched the first in a series of strategy papers, which will assess what the UK IVD industry needs to grow and thrive in the future. The first of these papers ’Emerging from the Pandemic – An Industry View’ examines what needs to be done to lock in our progress in developing systems to cope with infectious diseases. The outbreak of SARS-CoV-2 first detected in China in December 2019 has been challenging for countries...
Read More
May 13, 2021
IPSWICH, MA (May 10th, 2021) — New England Biolabs, Inc. (NEB®), a leading supplier of life science reagents, today announces that it has entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB. With the point-of-care market becoming more focused on the development of robust, accurate and cost-effective diagnostic tests for use outsi...
Read More
May 11, 2021
BIVDA Chief Executive Doris-Ann Williams and Chief Operating Officer Helen Dent have commented on the publication of the Health and Care Bill in today’s Queen’s Speech.  Commenting on plans to promote integrated care in the health service, Doris-Ann said; “The new White Paper offers an opportunity to promote joint working and collaboration in the NHS across different teams, department and disciplines. As part of these reforms, we want to see greater use of IVDs in pri...
Read More
May 07, 2021
BIVDA commentary on proposed validation of COVID Antigen tests for sale in the private sector7th May 2021 After careful consideration, BIVDA believes that setting up a separate validation process sets both an unwarranted precedent for the industry and undermines the regulatory system. Our position is that changes to the existing regulatory regime could achieve what the validation policy is trying to do, more effectively and without creating a two-layer system – a view in which we are ...
Read More
Apr 26, 2021
FluoretiQ Ltd. today announced the appointment of Mr Kasra Saeb-Parsy Consultant Urologist with Cambridge (UK) University Hospitals NHS Foundation Trust as their Chief Medical Officer. Mr. Saeb-Parsy will oversee and lead all clinical development, regulatory and medical affairs strategies and activities of the Company."I am delighted to welcome Kasra as our Chief Medical Officer at this key stage of our company growth as we approach clinical studies and regulatory approval in the UK and USA...
Read More
Page 1 of 11 FirstPrevious [1]